“…Some studies have shown low total cholesterol to be associated with increased risk of preterm birth (Bartha et al, ; Catov et al, ; Edison et al, ; Mudd et al, ; Oluwole, Adegbesan‐Omilabu, & Okunade, ); however, several studies have not shown such an association, which is consistent with our findings (Alleman et al, ; Harville et al, ; Kramer et al, ; Magnussen et al, ; Vrijkotte et al, ; Wiznitzer et al, ). The association between HDL‐C and duration of gestation in our study is similar to the results from other studies (Bartha et al, ; Kramer et al, ; Magnussen et al, ).…”
Low plasma cholesterol may be associated with preterm birth; however, results are mixed and limited primarily to high‐income countries. Our objective was to determine whether maternal plasma lipid concentrations are associated with pregnancy duration. We performed a nested cohort (n = 320) study of pregnant Ghanaian women enrolled in a randomized controlled trial. Total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol, and triglyceride concentrations were analyzed in plasma at ≤20and 36 weeks gestation as continuous variables and also categorized into low, referent, or high (<10th, 10th–90th, >90th percentile). At ≤20 weeks, plasma lipid concentrations were not associated with pregnancy duration. At 36 weeks, total cholesterol and triglyceride concentrations were not associated with pregnancy duration. Higher HDL‐C at 36 weeks was associated with a longer pregnancy duration (adjusted β‐coefficient ± standard error: 0.05 ± 0.02 days mg−1/dL, p = .02); pregnancy duration was 5.9 ± 2.0 (mean ± standard error) days shorter among women with low HDL‐C compared with the referent group (10th–90th percentile) (p = .02) and 8.6 ± 2.6 days shorter when compared with the high HDL‐C group (p = .003). Pregnancy duration was 4.9 ± 2.1 days longer among women with low low‐density lipoprotein cholesterol at 36 weeks gestation when compared with the referent group (p = .051). Our data suggest that low HDL‐C in the third trimester of pregnancy is associated with a shorter duration of pregnancy in this study population but do not support the hypothesis that low total cholesterol is associated with a shorter pregnancy duration.
“…Some studies have shown low total cholesterol to be associated with increased risk of preterm birth (Bartha et al, ; Catov et al, ; Edison et al, ; Mudd et al, ; Oluwole, Adegbesan‐Omilabu, & Okunade, ); however, several studies have not shown such an association, which is consistent with our findings (Alleman et al, ; Harville et al, ; Kramer et al, ; Magnussen et al, ; Vrijkotte et al, ; Wiznitzer et al, ). The association between HDL‐C and duration of gestation in our study is similar to the results from other studies (Bartha et al, ; Kramer et al, ; Magnussen et al, ).…”
Low plasma cholesterol may be associated with preterm birth; however, results are mixed and limited primarily to high‐income countries. Our objective was to determine whether maternal plasma lipid concentrations are associated with pregnancy duration. We performed a nested cohort (n = 320) study of pregnant Ghanaian women enrolled in a randomized controlled trial. Total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol, and triglyceride concentrations were analyzed in plasma at ≤20and 36 weeks gestation as continuous variables and also categorized into low, referent, or high (<10th, 10th–90th, >90th percentile). At ≤20 weeks, plasma lipid concentrations were not associated with pregnancy duration. At 36 weeks, total cholesterol and triglyceride concentrations were not associated with pregnancy duration. Higher HDL‐C at 36 weeks was associated with a longer pregnancy duration (adjusted β‐coefficient ± standard error: 0.05 ± 0.02 days mg−1/dL, p = .02); pregnancy duration was 5.9 ± 2.0 (mean ± standard error) days shorter among women with low HDL‐C compared with the referent group (10th–90th percentile) (p = .02) and 8.6 ± 2.6 days shorter when compared with the high HDL‐C group (p = .003). Pregnancy duration was 4.9 ± 2.1 days longer among women with low low‐density lipoprotein cholesterol at 36 weeks gestation when compared with the referent group (p = .051). Our data suggest that low HDL‐C in the third trimester of pregnancy is associated with a shorter duration of pregnancy in this study population but do not support the hypothesis that low total cholesterol is associated with a shorter pregnancy duration.
“…The sample size was estimated on the basis of previous studies, assuming a rate of preterm delivery of 10% for women with low serum vitamin D levels and 5% for those with normal serum vitamin D levels. Power analysis indicated that a minimum sample size of 103 women in each group (total sample size, 206 women) would be required to ensure at least 80% power to detect the anticipated between‐group differences, allowing for an attrition or non‐response rate of 10%.…”
Objective
To determine the association between low maternal vitamin D levels and preterm delivery among parturients in Lagos, Nigeria.
Methods
The present study was an analytical cross‐sectional study of women with preterm deliveries (defined as <37 weeks) and women with term deliveries (defined as ≥37 weeks) at the labor unit of Lagos University Teaching Hospital between December 1, 2015, and October 31, 2016. Relevant information was obtained via a proforma, and maternal venous samples were collected immediately after delivery. Serum 25‐hydroxy vitamin D was determined by a vitamin D enzyme‐linked immunoassay kit.
Results
The study enrolled 103 women in each group. The overall prevalence of vitamin D deficiency was 14.1% (29/206). 24 (23.3%) women with preterm delivery had low serum vitamin D (<30 ng/mL) as compared with only 5 (4.9%) women with term delivery (P<0.001). Compared with normal serum vitamin D levels, low maternal vitamin D had an approximately nine‐fold higher likelihood of preterm delivery (adjusted odds ratio 9.41, 95% confidence interval 2.42–36.54; P<0.001).
Conclusion
The prevalence of serum vitamin D deficiency was higher among women with preterm delivery than among those with term delivery. The potential role of prenatal vitamin D supplementation in the prevention of preterm delivery should be further investigated.
“…However, the evidence from this study would indicate that our current scientific understanding of the relationship between lipid metabolism, PTB, and genetics is incomplete. Although some studies have found increased risk for PTB among women with low TC during pregnancy or at delivery, (Edison et al, ; Heida et al, ; Oluwole et al, ) associations between high HDL‐C or low TAG and increased risk for PTB have not been previously identified. In interpreting these findings, it is important to recognize the degree to which the GRS explain variability in the lipid profile.…”
Section: Discussionmentioning
confidence: 99%
“…The associations between lipid components and PTB have been inconsistent across multiple studies (Alleman et al, ; Chatzi et al, ; Edison et al, ; Emet et al, ; Jelliffe‐Pawlowski et al, ; Jin et al, ; Kramer et al, ; Lei et al, ; Maymunah et al, ; Mudd et al, ; Niromanesh et al, ; Oluwole et al, ; Vrijkotte et al, ). These studies are centered on the hypothesis that extreme metabolic changes in pregnancy, as reflected by lipid profiles, confer increased risk for PTB.…”
Section: Introductionmentioning
confidence: 99%
“…These studies vary greatly in the lipid components that were measured, the gestational age at which they were measured, the inclusion and exclusion criteria, and the fasting status of the measurements, which likely contribute to their inconsistent results. Studies of maternal lipid profiles in late‐first to early‐second trimester found that low HDL‐C (Jelliffe‐Pawlowski et al, ; Kramer et al, ; Lei et al, ), high TAG (Jelliffe‐Pawlowski et al, ; Lei et al, ; Mudd et al, ; Niromanesh et al, ), low TC (Edison et al, ; Oluwole et al, ) or high TC (Maymunah et al, ; Mudd et al, ), and high LDL‐C:HDL‐C (Chatzi et al, ) were associated with increased risk for PTB. A recent meta‐analysis of these studies found that elevated TC, elevated TAG, and low HDL‐C were significantly associated with increased risk for PTB, with significant odds ratios ranging from 1.33 to 1.71 (Jiang et al, ).…”
Maternal lipid profiles are associated with risk for preterm birth (PTB), although the lipid component and effect size are inconsistent between studies. It is also unclear whether these associations are the result of excessive changes in lipid metabolism during pregnancy or genetic variability in genes controlling basal lipid metabolism. This study investigates the association between genetic risk scores (GRS) for four lipid components (high‐density lipoprotein [HDL‐C], low‐density lipoprotein [LDL‐C], triacylglycerols [TAG], and total cholesterol [TC]) with risk for PTB. Subjects included 954 pregnant women from California for whom second trimester serum samples were available, of which 479 gave birth preterm and 475 gave birth at term. We genotyped 96 single‐nucleotide polymorphisms, which were selected from genome‐wide association studies of lipid levels in adult populations. Lipid‐specific GRS were constructed for HDL‐C, LDL‐C, TAG, and TC. The associations between GRS and PTB were analyzed using logistic regression. A higher HDL‐C GRS was associated with increased risk for PTB overall and spontaneous PTB. Higher TAG and TC GRS were associated with decreased risk for PTB overall and spontaneous PTB. This study identifies counter‐intuitive associations between lipid GRS and spontaneous PTB. Further replication studies are needed to confirm these findings, but they suggest that our current scientific understanding of the relationship between lipid metabolism, PTB, and genetics is incomplete.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.